Mohammad Bahadoram
1,2 
, Bijan Keikhaei
1 , Shahram Rafie
2 , Esma'il Akade
3,1 , Najmeh Nameh Goshay Fard
1, Roozbeh Moghaddar
1,4* 1 Thalassemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
2 Department of Neurology, School of Medicine, Musculoskeletal Rehabilitation Research Center, Golestan Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
3 Department of Medical Virology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
4 Department of Pediatric Hematology and Oncology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
Abstract
Thrombotic thrombocytopenic purpura (TTP) is a type of microangiopathy, which is characterized by the formation of small blood clots in the vessels, leading to organ damage and low platelet count. In sickle cell disease (SCD), TTP can occur due to the activation of the coagulation system and damage to the endothelial cells lining the blood vessels. The importance of TTP in SCD lies in its potential to cause severe and life-threatening complications, including stroke, renal and heart failure. Early recognition and treatment of TTP in SCD are crucial to prevent these complications and improve outcomes. In this letter, we highlighted the significance of neurological complications in the diagnosis of TTP in SCD.